Fairfax, Virginia
Phase 3 cancer trials in Fairfax, VA
54 Phase 3 cancer studies are recruiting participants at sites in Fairfax as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Fairfax at a glance
- 54 studies are recruiting at a site in Fairfax.
- By phase: Phase 2/3 (6), Phase 3 (48).
- By sponsor: industry (47), university, hospital or other (7).
- By research area: Lung Cancer (22), Breast Cancer (15), Pancreatic Cancer (7), Prostate Cancer (5), Lymphoma (4), Melanoma (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Fairfax
Basic details from each study's public record (the 30 most recently updated of 54). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Daiichi Sankyo
- Study site
- Virginia Cancer Specialists
- Registry record
- NCT07683754 · updated
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study site
- Virginia Cancer Specialists, PC
- Registry record
- NCT06982521 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study site
- Inova Fairfax Hospital
- Registry record
- NCT05633654 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Inova Fair Oaks Hospital · Inova Schar Cancer Institute
- Registry record
- NCT06748222 · updated
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Virginia Cancer Specialists
- Registry record
- NCT07174336 · updated
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Virginia Cancer Specialists
- Registry record
- NCT07492641 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.
Lung cancer studies recruiting in Fairfax
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Virginia Cancer Specialists, PC
- Registry record
- NCT07195695 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Virginia Cancer Specialists ( Site 0167)
- Registry record
- NCT06623422 · updated
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Eikon Therapeutics
- Study site
- Virginia Cancer Specialists, PC
- Registry record
- NCT07365319 · updated
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Virginia Cancer Specialists ( Site 0114)
- Registry record
- NCT07554339 · updated
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SystImmune Inc.
- Study site
- Virginia Cancer Specialists
- Registry record
- NCT07625644 · updated
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07291037 · updated
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- USO - Virginia Cancer Specialists
- Registry record
- NCT06119581 · updated
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study sites
- Inova Schar Cancer · Virginia Cancer Specialists
- Registry record
- NCT06712316 · updated
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Phase 3
- Ages 18 to 90
- All sexes
- Sponsor
- ImmunityBio, Inc.
- Study site
- Virginia Cancer Specialists
- Registry record
- NCT06745908 · updated
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- ArriVent BioPharma, Inc.
- Study site
- Virginia Cancer Specialists
- Registry record
- NCT07185997 · updated
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Mirati Therapeutics Inc.
- Study site
- USOR - Virginia Cancer Specialists - Fairfax Office
- Registry record
- NCT04613596 · updated
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT06692738 · updated
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT06627647 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.
Prostate cancer studies recruiting in Fairfax
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- BioNTech SE
- Study site
- Virginia Cancer Specialists PC
- Registry record
- NCT07365995 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Virginia Cancer Specialists
- Registry record
- NCT07164443 · updated
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Virginia Cancer Specialists
- Registry record
- NCT07225946 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.
Melanoma studies recruiting in Fairfax
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Inova Schar Cancer Institute
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Fairfax, VA on ClinicalTrials.gov.
Lymphoma studies recruiting in Fairfax
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Nuvation Bio Inc.
- Study site
- Inova Schar Cancer Institute
- Registry record
- NCT05303519 · updated
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Inova Schar Cancer Institute ( Site 0015)
- Registry record
- NCT06136559 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Fairfax, VA on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Fairfax
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study sites
- Investigative Site US057 · Investigative Site US065
- Registry record
- NCT07522073 · updated
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immuneering Corporation
- Study site
- Virginia Cancer Specialists
- Registry record
- NCT07562152 · updated
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Inova Schar Cancer Institute Clinical Trials
- Registry record
- NCT07409272 · updated
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Virginia Cancer Specialists - Fairfax Office
- Registry record
- NCT06943755 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Fairfax, VA on ClinicalTrials.gov.
Ask about studies near Fairfax
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Virginia
All Virginia locations
139 studies recruiting across 40 cities.
Richmond
69 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections